A Phase 3 interventional study of SGT-003 and Placebo in Duchenne Muscular Dystrophy, sponsored by Solid Biosciences Inc.. Recruiting at 13 sites in 6 countries. Open to male participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Solid Biosciences Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies in Muscular Dystrophy, Duchenne with a site in Canada — 6 open to participants now, 15 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · Canada.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in Canada, this one is the 26th largest by planned enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2025, is one of 26 in phase 3, reaches primary completion later than 9 of the 14 other live ones, and was the 63rd registered.
482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.
Browse Muscular Dystrophy, Duchenne studies →6 of the 66 studies in Muscular Dystrophy, Duchenne with a site in Canada are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Canada, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Solid Biosciences Inc. · Sites in Canada, United States, Italy and 1 more country
Ages 0–17 · Men only
Italfarmaco · Sites in Canada, Belgium, Czechia and 9 more countries
Ages 9–17 · Men only
Italfarmaco · Sites in Canada, United States, Belgium and 8 more countries
Ages 7+ · Men only
NS Pharma, Inc. · Sites in Canada, United States, Australia and 4 more countries
Men only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.
This study: 7 Years to 11 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 29 · Phase 3 31 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 25 across 333 interventional studies indexed under Muscular Dystrophy, Duchenne.
Median enrollment 68 across the 62 interventional studies, 85 across the 3 observational. Of the 45 that completed or were terminated, 33 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 66 have an industry lead sponsor. The 10 most frequent:
Solid Biosciences Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Solid Biosciences Inc. has 4 studies filed under Muscular Dystrophy, Duchenne — fewer than ten, so there is no comparison to draw.
4 of the studies in Muscular Dystrophy, Duchenne with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05881408Phase 3Sarepta Therapeutics, Inc.A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | 2027-05-31 |
| NCT05996003NS Pharma, Inc.NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | 2027-02-26 |
| NCT07287189Satellos Bioscience, Inc.Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | 2027-03-31 |
| NCT06138639Solid Biosciences Inc.A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | 2027-05-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 66 studies in Muscular Dystrophy, Duchenne with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing date.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other Inclusion/Exclusion criteria to be applied as per protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enrolled participants will receive a single intravenous (IV) infusion of SGT-003 in Part 1 and may receive a single IV infusion of matching Placebo in Part 2 per protocol-defined eligibility criteria.
Drug: SGT-003 · Drug: Placebo
Enrolled participants will receive a single intravenous (IV) infusion of matching Placebo in Part 1 and a single IV infusion of SGT-003 in Part 2 per protocol-defined eligibility criteria.
Drug: SGT-003 · Drug: Placebo
Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)
IV infusion
Change From Baseline in Time to Rise (TTR) from Supine Velocity (rise/s) at Day 540
Time frame: Baseline, Day 540
Change From Baseline in Stride Velocity 95th Centile (SV95C) (m/s) at Day 540
Time frame: Baseline, Day 540
Change From Baseline in 4-Stair Climb (4SC) Velocity (Tasks/s) at Day 540
Time frame: Baseline, Day 540
Change From Baseline in North Star Ambulatory Assessment (NSAA) total score at Day 540
Time frame: Baseline, Day 540
Change From Baseline in 10-meter Walk/Run (10MWR) Velocity (m/s) at Day 540
Time frame: Baseline, Day 540
Cumulative Loss of Function in NSAA Items at Day 540
Time frame: At Day 540
Change from Baseline in Percent Predicted Forced Vital Capacity (FVC) at Day 540
Time frame: Baseline, Day 540
Change from Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Day 540
Time frame: Baseline, Day 540
Change from Baseline in Percent Predicted Forced Expiratory Volume in 1 second (FEV1) at Day 540
Time frame: Baseline, Day 540
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at Day 540[
Time frame: Baseline, Day 540
Change from Baseline in Global Longitudinal Strain (GLS) at Day 540
Time frame: Baseline, Day 540
Change from Baseline in the Pediatric Outcomes Data Collection Instrument (PODCI) Global score at Day 540
Time frame: Baseline, Day 540
Number of Participants with Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of special interest (AESIs), and clinically significant changes in Electrocardiogram (ECG) and Echocardiography (ECHO)
Time frame: From first dose up to Day 540
Change From Baseline in Viral Shedding as Measured by Polymerase Chain Reaction (PCR) at Day 360
Time frame: Baseline, Day 360
Change From Baseline in Anti-Adeno-Associated Virus (AAV) Antibody Titers at Day 540
Time frame: Baseline, Day 540
Change from Baseline in Microdystrophin T-cell Reactivity by Enzyme-Linked Immunospot at Day 540
Time frame: Baseline, Day 540
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jan 2029, 39 months after the start.
Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 39 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Muscular Dystrophy, Duchenne →
Solid Biosciences Inc.